Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The potential economic value of a human norovirus vaccine for the United States.

Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY.

Vaccine. 2012 Nov 19;30(49):7097-104. doi: 10.1016/j.vaccine.2012.09.040. Epub 2012 Sep 28.

2.

The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control.

Lopman BA, Steele D, Kirkwood CD, Parashar UD.

PLoS Med. 2016 Apr 26;13(4):e1001999. doi: 10.1371/journal.pmed.1001999. eCollection 2016 Apr. Review.

3.

Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.

Aliabadi N, Lopman BA, Parashar UD, Hall AJ.

Expert Rev Vaccines. 2015;14(9):1241-53. doi: 10.1586/14760584.2015.1073110. Epub 2015 Jul 29. Review.

PMID:
26224658
4.

Vaccine against norovirus.

Tan M, Jiang X.

Hum Vaccin Immunother. 2014;10(6):1449-56. doi: 10.4161/hv.28626. Epub 2014 May 5. Review.

5.

Norovirus.

Robilotti E, Deresinski S, Pinsky BA.

Clin Microbiol Rev. 2015 Jan;28(1):134-64. doi: 10.1128/CMR.00075-14. Review.

6.

Noroviruses: epidemiology, immunity and prospects for prevention.

Pringle K, Lopman B, Vega E, Vinje J, Parashar UD, Hall AJ.

Future Microbiol. 2015;10(1):53-67. doi: 10.2217/fmb.14.102. Review.

PMID:
25598337
7.

Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.

Richardson C, Bargatze RF, Goodwin R, Mendelman PM.

Expert Rev Vaccines. 2013 Feb;12(2):155-67. doi: 10.1586/erv.12.145. Review.

PMID:
23414407
8.

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.

9.

[Gastroenteritis due to norovirus].

Katayama K.

Nihon Naika Gakkai Zasshi. 2004 Nov 10;93(11):2334-40. Review. Japanese. No abstract available.

PMID:
15624468
10.

[Norovirus gastroenteritis in adult].

Kanda A.

Nihon Rinsho. 2012 Aug;70(8):1371-5. Review. Japanese.

PMID:
22894075
11.

Noroviruses: agents in outbreaks of acute gastroenteritis.

Thornton AC, Jennings-Conklin KS, McCormick MI.

Disaster Manag Response. 2004 Jan-Mar;2(1):4-9. Review.

PMID:
14760287
12.

The burden of norovirus gastroenteritis: an important foodborne and healthcare-related infection.

Belliot G, Lopman BA, Ambert-Balay K, Pothier P.

Clin Microbiol Infect. 2014 Aug;20(8):724-30. doi: 10.1111/1469-0691.12722. Review.

13.

[Norovirus (infants/children)].

Onishi S.

Nihon Rinsho. 2012 Aug;70(8):1366-70. Review. Japanese.

PMID:
22894074
14.

[Noroviruses: most frequent cause of infectious gastroenteritis].

Schneider T, Schreier E, Zeitz M.

Dtsch Med Wochenschr. 2007 Oct;132(43):2261-6. Review. German. No abstract available.

PMID:
17940932
15.

Norovirus: targets and tools in antiviral drug discovery.

Rocha-Pereira J, Neyts J, Jochmans D.

Biochem Pharmacol. 2014 Sep 1;91(1):1-11. doi: 10.1016/j.bcp.2014.05.021. Epub 2014 Jun 2. Review.

PMID:
24893351
16.

[Epidemic and control strategy on nosocomial outbreak of norovirus gastroenteritis].

Xu Q.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Oct;30(5):614-7. Review. Chinese.

17.

Status of vaccine research and development for norovirus.

Riddle MS, Walker RI.

Vaccine. 2016 Jun 3;34(26):2895-2899. doi: 10.1016/j.vaccine.2016.03.077. Epub 2016 Mar 29. Review.

18.

Systematic review of the economic value of diarrheal vaccines.

Rheingans R, Amaya M, Anderson JD, Chakraborty P, Atem J.

Hum Vaccin Immunother. 2014;10(6):1582-94. doi: 10.4161/hv.29352. Epub 2014 May 27. Review.

19.

Tropical and travel-associated norovirus: current concepts.

Ballard SB, Saito M, Mirelman AJ, Bern C, Gilman RH.

Curr Opin Infect Dis. 2015 Oct;28(5):408-16. doi: 10.1097/QCO.0000000000000197. Review.

20.

Prospects and Challenges in the Development of a Norovirus Vaccine.

Cortes-Penfield NW, Ramani S, Estes MK, Atmar RL.

Clin Ther. 2017 Aug;39(8):1537-1549. doi: 10.1016/j.clinthera.2017.07.002. Epub 2017 Jul 26. Review.

PMID:
28756066

Supplemental Content

Support Center